| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |